Sumitomo Life Insurance Co. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 9.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,705 shares of the biopharmaceutical company’s stock after selling 1,839 shares during the period. Sumitomo Life Insurance Co.’s holdings in Gilead Sciences were worth $1,215,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $1,649,000. Tennessee Valley Asset Management Partners acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $49,000. Flputnam Investment Management Co. boosted its position in Gilead Sciences by 15.8% in the fourth quarter. Flputnam Investment Management Co. now owns 6,070 shares of the biopharmaceutical company’s stock valued at $492,000 after buying an additional 826 shares in the last quarter. Tyche Wealth Partners LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $420,000. Finally, TRUE Private Wealth Advisors acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $208,000. Institutional investors and hedge funds own 83.67% of the company’s stock.
Insider Buying and Selling
In related news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.
Gilead Sciences Stock Down 0.8 %
Gilead Sciences Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.17%. The ex-dividend date is Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the stock. TD Cowen dropped their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Truist Financial raised their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday. BMO Capital Markets raised their price target on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research note on Wednesday, April 24th. Finally, StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Twelve investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $81.94.
Get Our Latest Research Report on Gilead Sciences
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
- Five stocks we like better than Gilead Sciences
- Canadian Penny Stocks: Can They Make You Rich?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is the NASDAQ Stock Exchange?
- MarketBeat Week in Review – 8/12 – 8/16
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.